Clinical trials
Phase 1 clinical trials
Below are recruiting phase 1 clinical trials, each written for real people, not researchers. We’re tracking 303 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07788014RecruitingPhase 1
Testing a new medicine for healthy adults
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
Adelaide, South AustraliaAges 18–65 - NCT07784699RecruitingPhase 1
Testing an experimental pill for weight loss in healthy or overweight adults
This study tests an experimental pill (GZC8072) for weight loss. It is a phase 1 trial, meaning it is one of the first times the drug is given to people, and the focus is on safety and how the body handles it. You would receive either a single dose (if you are healthy) or multiple doses (if you are overweight or obese) to see how the medication works.
BeijingAges 18–55 - NCT07757802RecruitingPhase 1
HIV vaccine nanoparticle and mRNA booster for healthy adults
This study tests a new HIV vaccine that uses tiny particles (nanoparticles) and an mRNA booster — similar to some COVID vaccines. The goal is to see if it is safe and helps your body fight HIV. It's for healthy adults who do not have HIV.
San Francisco, CaliforniaAges 18–55 - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Orlando, FloridaAges 18 years+ - NCT06589609RecruitingPhase 1
FluBHPVE6E7 immunotherapy for HPV16-positive oropharyngeal cancer
This trial tests a new immunotherapy called FluBHPVE6E7 for people with HPV16-positive oropharyngeal cancer that has not spread to distant parts of the body. The treatment is given directly into the tumor to help the immune system fight the cancer.
ViennaAges 18–65 - NCT07745907RecruitingPhase 1
A first-in-human study of a new drug in healthy Chinese and Japanese adults
This trial tests a single dose of an investigational drug called AMG 691 in healthy Chinese and Japanese volunteers to see how it is processed by the body and how safe it is. This is an early-phase study, so it may help make future treatments safer for people of similar backgrounds.
Las Vegas, NevadaAges 18–60 - NCT07726147RecruitingPhase 1
Testing a new allergy shot for Japanese cedar pollen
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
Tokyo, Shinjuku-kuAges 18–65 - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Queen Creek, ArizonaAges 18 years+ - NCT07706686RecruitingPhase 1
Dengue challenge study in people with prior infection
This study tests how the body responds to a mild, lab-made dengue virus in people who have had dengue before. It looks at how the immune system reacts to a second infection, which may help improve future vaccines and treatments.
Bethesda, MarylandAges 18–50 - NCT07712939RecruitingPhase 1
Study of CND319 for rheumatic diseases
This study tests a new drug called CND319 in healthy volunteers and people with rheumatoid arthritis or Sjögren's disease. The goal is to see if it is safe and how the body responds to it.
Melbourne, VictoriaAges 18–65 - NCT04093466RecruitingPhase 1
Testing a new pill for advanced solid tumors
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT07694557RecruitingPhase 1
Safety and immune response study of YKYY025 RSV vaccine
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Anning, YunnanAges 18 years+ - NCT07695831RecruitingPhase 1
Testing a new drug (GEN1119) for solid tumors
This trial tests a new experimental drug called GEN1119 for people with solid tumors that have stopped responding to standard treatments. It's an early-phase study to see if the drug is safe and how well it works.
Rennes, Ille Et VilaineAges 18 years+ - NCT07696065RecruitingEarly Phase 1
Palliative care support for kids in early cancer trials
This study tests adding palliative care—extra comfort and quality-of-life support—for children and young adults being considered for early-phase cancer trials. It involves patients, their families, and their doctors.
Phoenix, ArizonaAges birth–25 years - NCT07665892RecruitingPhase 1
Testing a new asthma drug in adults
This study tests a new medication called ASY202 for adults with stable asthma. The goal is to see if it's safe and how the body processes it. It may be an option for those who have not had a recent asthma attack or infection.
Glendale, ArizonaAges 18–55 - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Grand Rapids, MichiganAges 18 years+ - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT07644650RecruitingPhase 1
Study of MST-168 for advanced solid tumors
This study tests a new drug called MST-168 for people with advanced solid tumors (cancers that have spread or can't be removed). It aims to find out if the drug is safe and effective, and how the body handles it, which could lead to a new treatment option for those who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT05667194RecruitingPhase 1
Early study of KH617 for advanced brain and solid tumors
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07610941RecruitingPhase 1
Testing a new cancer drug alone and combined with others
This early-stage trial tests a new experimental drug (MST-0312) in people with solid tumors like lung cancer, melanoma, bladder cancer, colorectal cancer, or triple-negative breast cancer. The goal is to find safe doses and see how well it works, either by itself or paired with other treatments.
BarcelonaAges 18 years+ - NCT05995782RecruitingPhase 1
Testing safety of FB418 in healthy people
This trial studies a new drug called FB418 to see if it's safe and how the body handles it. It first tests single doses in younger healthy men, then multiple doses, and also includes an optional group for healthy older adults.
SeoulAges 19 years+ - NCT07595458RecruitingPhase 1
Safety Study of JST-018 Immune Treatment in Healthy Adults
This is a first-in-human safety study testing a new experimental immune therapy called JST-018. Researchers want to see how safe it is, how well your body tolerates it, and how your body processes it when given as an injection.
Las Vegas, NevadaAges 18–55
Hear when a new Phase 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 1?
- Yes. Clin2 currently lists 303 recruiting phase 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.